GGrantIndex
← Leaderboards

Everett E Vokes

University Of Chicago

$4,130,384
Attributed
$4,130,384
Total exposure
6
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.7M · FY200612
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12

Funding mix

By agency

NIH$5,391,460 · 7

By mechanism

N01$3,041,406 · 2
P50$1,261,076 · 1
P30$768,445 · 3
U01$320,533 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Chicago

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchClinical TrialsFacultyFundingCytotoxic AgentEnrollmentAntineoplastic AgentsCancer PatientDrug KineticsFosteringCancer And Leukemia Group BChicagoClinical InvestigatorCytostaticsDirect CostsGenotypeClinical Trials Cooperative GroupClinical Trials DesignConduct Clinical TrialsCombined Modality TherapyDrug DevelopmentCollaborationsChemotherapyGrant

Grant awards (20)

PROGRAM 4 (CLINICAL AND EXPERIMENTAL THERAPEUTICS)$38,634
P30 · FY2012 · CA · contact PI
PROGRAM 4 (CLINICAL AND EXPERIMENTAL THERAPEUTICS)$40,511
P30 · FY2011 · CA · contact PI
PROGRAM 4 (CLINICAL AND EXPERIMENTAL THERAPEUTICS)$44,110
P30 · FY2010 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$654,110
N01 · FY2009 · CA · contact PI
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8418 UNDER$650,000
N01 · FY2009 · CA · contact PI
PROGRAM 4 (CLINICAL AND EXPERIMENTAL THERAPEUTICS)$40,312
P30 · FY2009 · CA · contact PI
PROGRAM 4 (CLINICAL AND EXPERIMENTAL THERAPEUTICS)$25,446
P30 · FY2008 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$1,737,296
N01 · FY2007 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS-261622001$0
N01 · FY2006 · CM · contact PI
CARCINOGENESIS AND NOVEL THERAPEUTICS IN ORAL CANCER$426,346
P50 · FY2001 · DE
CARCINOGENESIS AND NOVEL THERAPEUTICS IN ORAL CANCER$4,553
P50 · FY2001 · DE
CORE--PROTOCOL AND DATA MANAGEMENT OFFICE$0
P30 · FY2001 · CA
CORE--PROTOCOL AND DATA MANAGEMENT OFFICE$0
P30 · FY2001 · CA
PLANNING AND EVALUATION$0
P30 · FY2001 · CA
PLANNING AND EVALUATION$0
P30 · FY2001 · CA
CARCINOGENESIS AND NOVEL THERAPEUTICS IN ORAL CANCER$827,856
P50 · FY2000 · DE
COOPERATIVE STUDY$320,533
U01 · FY2000 · CA
CORE--PROTOCOL AND DATA MANAGEMENT OFFICE$289,716
P30 · FY2000 · CA
PLANNING AND EVALUATION$289,716
P30 · FY2000 · CA
CARCINOGENESIS AND NOVEL THERAPEUTICS IN ORAL CANCER$2,321
P50 · FY2000 · DE